Quartz·1 min read·medium
Novartis is licensing an mRNA autoimmune therapy from China's Abogen for up to $7.8 billion
✦AI Summary
Novartis has entered into a licensing agreement with Chinese biotech firm Abogen to develop an mRNA-based autoimmune therapy. The deal includes an upfront payment of $575 million with potential milestone payments reaching up to $7.8 billion.
Why it matters
This deal underscores the growing trend of Western pharmaceutical giants partnering with Chinese biotech firms to access cutting-edge mRNA technology for non-vaccine applications.
The Swiss drugmaker will pay $575 million upfront to license…
Also covering this story
One other newsroom covered this event. We read that version too.
businesshealthscience
✦
Get smarter about the news
Sign up free for a feed built around what you actually care about, Dive Deeper research on any story, and the full text of every article.
Create free accountAlready have an account? Sign in